Welcome to our dedicated page for EXPONENT SEC filings (Ticker: EXPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exponent Inc filings document operating results, Regulation FD disclosures, capital-return actions, and governance matters for a science and engineering consulting company. Recent Form 8-K reports record quarterly financial results, dividend declarations, and share repurchase authorizations tied to the company’s common stock.
Proxy materials cover shareholder voting matters, director elections, executive compensation, pay-versus-performance tables, and board governance. The filing record also includes material-event disclosures related to leadership and corporate governance, along with capital-structure disclosures relevant to Exponent’s public-company reporting.
Exponent Inc. reported that CEO Catherine Corrigan exercised non-qualified stock options for 2,379 shares of common stock at $29.05 per share and on the same date sold 1,737 shares at $62.7776 per share to cover the option exercise price and taxes. After these trades, she directly held 115,771 common shares, and the transactions were effected under a Rule 10b5-1 trading plan.
Catherine Corrigan has filed a notice of proposed sale for 1,737 shares of EXPO common stock, expected on 07/15/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares are shown as acquired that day via cash exercise of stock options. The notice also lists 10b5-1 sales of 4,119 and 4,194 EXPO shares on 06/15/2026 and 05/15/2026, with stated values of $235,303.23 and $226,725.54, respectively.
Exponent Inc. CEO Catherine Corrigan exercised stock options to acquire 7,872 shares of common stock. The options were exercised at an effective price of $25.405 per share, converting an incentive stock option grant into common shares.
Following this exercise, Corrigan directly holds 115,129 shares of Exponent common stock. The derivative position tied to this option grant was reduced to zero, and there was no reported same-day sale, indicating an exercise-and-hold transaction. A footnote notes the stock option became exercisable in four equal annual installments.
Exponent Inc. President & CEO Catherine Corrigan reported an option exercise and related stock sales in Exponent Inc. common stock. On June 15, 2026, she exercised non-qualified stock options covering 5,605 shares at exercise prices of $29.05 and $25.405 per share.
On the same date, she executed open-market sales totaling 4,119 shares at an average price of $57.1263 per share to cover the option exercise price and taxes, according to the footnote. After these transactions, she directly holds 106,670 shares of Exponent common stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice proposing the sale of 4,119 shares of Common stock on 06/15/2026, described as an exercise of stock options with cash as the consideration method. The filing also lists prior 10b5-1 sales by Catherine Corrigan on 05/15/2026, 04/15/2026, and 03/16/2026, showing 4,194, 3,909, and 3,912 shares respectively and reported dollar amounts for each sale.
Exponent, Inc. reported the results of its annual meeting of stockholders held on June 4, 2026. A total of 48,614,692 shares of common stock were outstanding as of April 8, 2026, the record date.
Stockholders elected six directors: George H. Brown, Catherine Ford Corrigan, Ph.D., Carol Lindstrom, Karen A. Richardson, Richard L. Schlenker Jr., and Debra L. Zumwalt. Committee memberships were updated, and Karen Richardson was appointed Chairman of the Board. Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending January 1, 2027, and approved on an advisory basis the fiscal 2025 compensation of named executive officers.
Exponent Inc. director Carol Lindstrom reported compensation-related equity activity and no open-market trades. She received a grant of 2,859 Restricted Stock Units (RSUs) that will cliff-vest on the day prior to the company’s next annual shareholder meeting. She also exercised 2,009 previously granted RSUs into 2,009 shares of Common Stock on a 1-for-1 basis, leaving no remaining RSUs from that prior grant. Following these transactions, she directly holds 9,405 shares of Common Stock. All transactions were recorded at a price of $0.00 per share, reflecting equity awards and a derivative conversion rather than market purchases or sales.
Exponent Inc. director George H. Brown received a grant of 2,859 Restricted Stock Units on June 4, 2026, which will cliff-vest before the company’s next annual shareholder meeting. On June 3, 2026, he also exercised 2,009 previously vested RSUs on a 1-for-1 basis into Common Stock, bringing his direct Common Stock holdings to 10,730 shares.
Exponent Inc director Karen A. Richardson reported equity compensation activity and updated holdings. She received a grant of 2,859 Restricted Stock Units (RSUs) that will cliff-vest on the day prior to the company’s next annual shareholder meeting, meaning all units vest at once.
She also exercised 2,009 previously vested RSUs into 2,009 shares of common stock on a 1-for-1 basis at no cash cost, leaving 2,009 common shares held directly. A separate entry shows 32,232 common shares held indirectly through a trust, reflecting additional ownership outside her personal account.
Exponent Inc director Debra Zumwalt reported routine equity compensation activity. On June 4, 2026, she received a grant of 2,859 Restricted Stock Units, which will cliff-vest before the company’s next annual shareholder meeting. On June 3, 2026, she exercised 2,009 RSUs into the same number of common shares on a 1:1 basis, bringing her direct common stock holdings to 31,830 shares.